z-logo
open-access-imgOpen Access
Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase‐mediated loss of barrier function and inflammation
Author(s) -
Gilbert Shila,
Zhang Rongli,
Denson Lee,
Moriggl Richard,
Steinbrecher Kris,
Shroyer Noah,
Lin James,
Han Xiaonan
Publication year - 2012
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201100192
Subject(s) - myosin light chain kinase , barrier function , microbiology and biotechnology , intestinal mucosa , enterocyte , biology , cancer research , wound healing , phosphorylation , immunology , medicine , endocrinology , small intestine
Epithelial myosin light chain kinase (MLCK)‐dependent barrier dysfunction contributes to the pathogenesis of inflammatory bowel diseases (IBD). We reported that epithelial GM‐CSF–STAT5 signalling is essential for intestinal homeostatic response to gut injury. However, mechanism, redundancy by STAT5 or cell types involved remained foggy. We here generated intestinal epithelial cell (IEC)‐specific STAT5 knockout mice, these mice exhibited a delayed mucosal wound healing and dysfunctional intestinal barrier characterized by elevated levels of NF‐κB activation and MLCK, and a reduction of zonula occludens expression in IECs. Deletion of MLCK restored intestinal barrier function in STAT5 knockout mice, and facilitated mucosal wound healing. Consistently, knockdown of stat5 in IEC monolayers led to increased NF‐κB DNA binding to MLCK promoter, myosin light chain phosphorylation and tight junction (TJ) permeability, which were potentiated by administration of tumour necrosis factor‐α (TNF‐α), and prevented by concurrent NF‐κB knockdown. Collectively, enterocyte STAT5 signalling protects against TJ barrier dysfunction and promotes intestinal mucosal wound healing via an interaction with NF‐κB to suppress MLCK. Targeting IEC STAT5 signalling may be a novel therapeutic approach for treating intestinal barrier dysfunction in IBD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here